A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy

NCT04354727 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Sponsor decision

Conditions

Myelofibrosis

Interventions

DRUG: APG-1252
DRUG: Ruxolitinib

Sponsor

Ascentage Pharma Group Inc.